3
Clinical Trials associated with HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate chemotherapy.
/ Unknown statusPhase 1IIT Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer
The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.
100 Clinical Results associated with HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)
100 Translational Medicine associated with HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)
100 Patents (Medical) associated with HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)
100 Deals associated with HLA-A*0201 Restricted Peptide Vaccine(University of Tokyo)